Fosamax (Alendronate) Pediatric Monitoring: What Clinicians Need to Know for Children Under 12

Why Alendronate Is Used in Young Children

Alendronate is prescribed off-label to children under 12 who have osteogenesis imperfecta, glucocorticoid-induced osteoporosis, or other secondary causes of low bone mineral density that carry a genuine fracture risk. The drug inhibits osteoclast-mediated bone resorption by binding hydroxyapatite at sites of active remodeling, reducing bone turnover markers within weeks of starting treatment. Because growing bone remodels continuously, the pharmacodynamic stakes in this age group differ meaningfully from those in post-menopausal adults.

The FDA has not granted a standard pediatric indication for alendronate in children under 18 for osteoporosis management outside of osteogenesis imperfecta type I in specific contexts, which means prescribers bear a higher documentation burden. The package insert for Fosamax (alendronate sodium, Merck) states that safety and efficacy in pediatric patients have not been established for most indications. That language does not prohibit use. It obliges the treating physician to justify the benefit-risk calculation in the medical record and to structure a monitoring plan accordingly.

The most widely cited adult fracture-prevention data come from the Fracture Intervention Trial (FIT), in which alendronate 5 to 10 mg daily produced a 47% relative reduction in vertebral fractures over 3 years in post-menopausal women with low bone mineral density (N=2 to 027 in the vertebral fracture arm) [1]. Extrapolating those findings to children is not straightforward, but FIT provides the mechanistic proof that osteoclast suppression translates to structural bone benefit, which underpins the pediatric rationale.

Pediatric endocrinologists generally consider alendronate when a child under 12 has a lumbar spine Z-score below -2.0 on DXA combined with a clinically significant fracture history, or when bone loss is accelerating on high-dose glucocorticoid therapy. A single low-trauma vertebral fracture in a child with an underlying bone fragility condition is typically enough to prompt pharmacologic intervention.

Baseline Workup Before the First Dose

Every child under 12 should complete a structured baseline evaluation before starting alendronate. Skipping any component of this workup increases the chance of dosing into an unrecognized contraindication.

The mandatory pre-treatment labs include serum calcium, phosphate, magnesium, alkaline phosphatase (ALP), creatinine with estimated GFR, 25-hydroxyvitamin D, and parathyroid hormone. Alendronate can precipitate hypocalcemia, particularly in children with vitamin D insufficiency, and a 25-OH vitamin D below 20 ng/mL should be corrected before the first dose rather than concurrently [2]. Waiting 6 to 8 weeks of vitamin D repletion is reasonable in most cases.

DXA of the lumbar spine (L1, L4) is the standard baseline bone density measure. The International Society for Clinical Densitometry (ISCD) Pediatric Position Statement recommends using age-, sex-, and ideally height-adjusted Z-scores rather than T-scores for all patients under 20, because T-scores reference a young adult peak bone mass that children have not yet reached [3]. A Z-score at or below -2.0 is the diagnostic threshold for "low bone density for chronological age" in children.

A practical pre-treatment checklist for this age group:

1. Lumbar spine DXA with height-for-age Z-score adjustment
2. Full metabolic panel including calcium, phosphate, magnesium, and creatinine
3. 25-OH vitamin D (correct to above 20 ng/mL before starting)
4. PTH to rule out secondary hyperparathyroidism driving bone loss
5. ALP as a baseline bone turnover marker
6. Height and weight plotted on a growth chart (WHO or CDC curves as appropriate for age)
7. Lateral spine radiograph or vertebral fracture assessment (VFA) by DXA to document baseline vertebral morphology
8. Dental evaluation, given the low but non-zero risk of osteonecrosis of the jaw with bisphosphonate use

Creatinine clearance below 35 mL/min is a hard contraindication listed in the alendronate prescribing information. Alendronate is renally cleared, and impaired excretion leads to excessive skeletal retention of the drug [4]. Children with renal disease require an alternative approach or specialist nephrology co-management before bisphosphonate therapy is considered.

Weight-Based Dosing in Children Under 12

Dosing alendronate in children under 12 requires a weight-based calculation rather than the fixed adult tablet doses. The most commonly used pediatric dose is 1 mg/kg once weekly, with a maximum of 35 mg per dose for children who have not yet reached the weight threshold where adult dosing applies, and 40 mg once weekly is sometimes cited in institutional protocols for older children approaching adolescence. No FDA-approved weight-based dosing table exists for this age group in the alendronate package insert, so clinicians rely on published cohort data and pediatric endocrinology society consensus.

Alendronate oral solution (70 mg/75 mL) may be easier to dose precisely in small children than splitting tablets. Tablets must never be chewed or dissolved in the mouth because the high pH can cause oropharyngeal ulceration. The oral solution formulation simplifies flexible dosing but requires the same administration precautions.

Administration technique is critical and deserves explicit parent and caregiver education at every visit. The child must take alendronate with a full glass (6, 8 oz) of plain water first thing in the morning, at least 30 minutes before any other food, drink, or medication, and must remain upright for at least 30 minutes after dosing. Lying down within 30 minutes of ingestion raises esophageal contact time and is the dominant cause of drug-induced esophagitis in this drug class [5]. Children who cannot reliably comply with upright positioning (because of neurological impairment, for example) may not be good candidates for oral bisphosphonate therapy. Intravenous pamidronate or zoledronic acid are often preferred in that clinical scenario.

Interval Monitoring: What to Check and How Often

Once alendronate has been started, the monitoring schedule should be structured but calibrated to disease severity. Children with rapidly progressive bone loss or high fracture burden need more frequent surveillance than those on stable low-dose glucocorticoid therapy with a single historical fracture.

Clinic visits. Children under 12 on alendronate should be seen at minimum every 3 to 6 months for the first year. Each visit should include height (stadiometer, not patient report), weight, pubertal staging by Tanner scale, and a focused review of gastrointestinal symptoms. Height velocity is the most sensitive early signal of a growth disturbance. A deceleration in height velocity crossing two major percentile lines on a standard growth chart warrants investigation before attributing it to the underlying bone disease.

Biochemistry. Serum calcium, phosphate, creatinine, and ALP should be checked at 3 months after initiation and then at least every 6 months. Bone-specific ALP or serum CTX (C-terminal telopeptide) can quantify the degree of osteoclast suppression and confirm the drug is having its intended pharmacodynamic effect. A fall in serum CTX of 40 to 60% from baseline after 3 months of weekly alendronate is consistent with adequate osteoclast inhibition in adults; whether the same threshold applies to children has not been formally validated, but it is used clinically as a qualitative signal [6].

Asymptomatic hypocalcemia after initiating bisphosphonate therapy is not rare in children with pre-existing vitamin D insufficiency. Checking serum calcium at the 3-month mark catches this before it becomes symptomatic. Calcium supplementation of 500, 1 to 000 mg of elemental calcium per day (in divided doses) is standard practice during alendronate therapy in this age group, guided by ISCD and the American Academy of Pediatrics nutritional recommendations [3].

DXA rescanning. The ISCD Pediatric Position Statement recommends rescanning no more frequently than every 12 months in most children, because the precision error of DXA relative to expected annual bone density change means scans done less than 12 months apart rarely cross the least significant change threshold and can mislead clinical decisions [3]. In children with very rapid bone loss, such as those on high-dose pulse glucocorticoid therapy, a 12-month interval is appropriate. In stable patients responding well, a 24-month interval may be sufficient for ongoing surveillance once the treatment response is established.

Each DXA report should document the same skeletal site (L1, L4 lumbar spine), the same machine if possible, and a comparison with the prior scan using absolute BMD (g/cm2) rather than Z-score alone, because Z-scores can appear stable even when absolute BMD is falling if the normative reference database is changing with age.

Vertebral morphometry. Annual lateral spine imaging or VFA is reasonable in children with a prior vertebral fracture, given that new vertebral fractures can be clinically silent. A child who reports sudden mid-back pain between scheduled visits should have a lateral spine radiograph at that visit rather than waiting for the annual surveillance window.

Growth and Pubertal Development Surveillance

Children under 12 are in active skeletal growth and often approaching puberty, which is the dominant driver of peak bone mass acquisition. Alendronate deposits into mineralizing bone and remains there for years after the drug is stopped. This long skeletal residence time raises a theoretical concern about whether bisphosphonate incorporation into growth plate cartilage could impair longitudinal bone growth.

Data on this question are reassuring but limited. A 2-year open-label study of alendronate in 139 children with osteogenesis imperfecta (mean age 8.7 years, dose range 1 to 2 mg/kg/week) found no statistically significant difference in height Z-score trajectory compared with historical controls over 24 months [7]. Linear growth appeared preserved. The study was not powered to detect small effects, and long-term follow-up into adulthood was not reported.

Tanner staging at each visit matters because puberty accelerates bone remodeling. A child entering puberty during bisphosphonate therapy will have higher rates of bone turnover than a pre-pubertal child, which changes the pharmacodynamic context. Some pediatric endocrinologists reduce alendronate dose or transition to a drug holiday during active puberty to allow normal remodeling-driven bone elongation to proceed. That decision should be made jointly with the pediatric endocrinologist managing the underlying condition.

Weight gain or loss also shifts the mg/kg dose. A child who has gained 5 kg since the last dose adjustment should have the dose recalculated. Clinicians sometimes miss this step at busy follow-up visits, leading to relative underdosing in growing children.

Dental and Orofacial Monitoring

Osteonecrosis of the jaw (ONJ) is a rare but serious adverse event associated with bisphosphonate use, most commonly reported in adults receiving high-dose intravenous bisphosphonates for malignancy-related bone disease. Pediatric cases of ONJ associated with oral alendronate at osteoporosis doses are extremely rare in the published literature. A 2021 systematic review identified fewer than 15 reported pediatric cases of bisphosphonate-related ONJ across all bisphosphonate types and routes of administration, and none were definitively attributed to oral alendronate at doses used for osteoporosis [8].

Despite the low absolute risk, a pre-treatment dental evaluation is standard practice, as the American Association of Oral and Maxillofacial Surgeons recommends optimizing dental health before starting bisphosphonate therapy. Invasive dental procedures such as extractions should be completed before the first dose when possible, or timed during a treatment gap if the procedure is non-urgent. Parents should be instructed to report any jaw pain, swelling, or non-healing oral sores promptly.

Calcium and Vitamin D Cotherapy

Alendronate should never be given without adequate calcium and vitamin D. Bisphosphonate-induced suppression of bone resorption transiently reduces serum calcium, which triggers secondary PTH elevation that can blunt the drug's effect on BMD if calcium stores are marginal. The Institute of Medicine dietary reference intake for calcium in children aged 4, 8 is 1 to 000 mg/day; for ages 9, 13, it rises to 1 to 300 mg/day [9]. Dietary calcium should be accounted for first, with supplements added to fill any gap.

Vitamin D target for children on bisphosphonate therapy is a 25-OH vitamin D above 20 ng/mL at minimum, with many pediatric endocrinologists preferring a level above 30 ng/mL for children with active bone disease. Vitamin D3 (cholecalciferol) is the preferred supplementation form. Doses of 600, 1 to 000 IU/day are adequate for maintenance in most children without malabsorption; children with osteogenesis imperfecta or inflammatory bowel disease may need 2 to 000 IU/day or more to maintain adequate levels, with quarterly monitoring of 25-OH vitamin D until levels stabilize [10].

When to Pause or Discontinue Alendronate

The concept of a drug holiday, well established in adult bisphosphonate management, applies differently in children. In adults, an alendronate holiday after 3 to 5 years of treatment is recommended by the American Society for Bone and Mineral Research because bisphosphonate accumulates in bone and residual effect persists for years after stopping. In children, the calculus is different: the underlying disease driving bone loss (osteogenesis imperfecta, glucocorticoid use) may still be active, and stopping prematurely may allow rapid bone loss to resume.

A pediatric drug holiday is generally considered when:

• The underlying disease is in remission or the precipitating glucocorticoid has been tapered off
• Bone density has returned to a Z-score above -1.0 on two consecutive annual DXA scans
• The child is entering puberty, where endogenous sex steroids will drive substantial bone mass accrual naturally
• An adverse event such as symptomatic hypocalcemia or persistent gastrointestinal intolerance has occurred

During a drug holiday, DXA monitoring every 12 to 24 months should continue. Serum CTX can rise to baseline within 12 to 18 months of stopping oral alendronate in adults; similar data in children are sparse, but a substantial rise in CTX suggests the osteoclast-suppressive effect has worn off and clinical re-evaluation is appropriate.

Communicating With Families

Families of children under 12 receiving alendronate frequently express concern about long-term skeletal effects. A practical, honest conversation should cover three points.

First, the available data from osteogenesis imperfecta cohort studies suggest that alendronate reduces fracture frequency and may improve vertebral morphology in children with bone fragility without measurable harm to longitudinal growth over 2 to 4 years of follow-up. The longest published follow-up in this age group is approximately 4 years, and true lifetime data do not yet exist.

Second, the risks of untreated bone fragility in a child with osteogenesis imperfecta or severe glucocorticoid-induced osteoporosis include repeated painful fractures, vertebral compression, spinal deformity, and chronic pain, all of which carry greater certainty of harm than the theoretical long-term bisphosphonate risks.

Third, the monitoring plan protects the child. Regular DXA, labs, and growth checks are not merely administrative. They allow dose adjustments, early detection of hypocalcemia, and timely identification of any growth signal that warrants reconsideration of the drug.

The American Academy of Pediatrics policy on off-label drug use states: "Physicians should not feel constrained from prescribing a drug for an unlabeled use when, in their professional judgment, such use is warranted by the patient's condition." That position supports alendronate use in this context when the clinical case is documented rigorously.

Special Populations Within This Age Group

Osteogenesis imperfecta (OI). OI types III and IV carry the highest fracture burden and the strongest evidence base for bisphosphonate use in children. Intravenous pamidronate has the largest pediatric evidence base for OI, but oral alendronate is used as an alternative or step-down therapy, particularly after intravenous loading cycles have been completed. The Montreal cohort data (Glorieux et al.) established that cyclic pamidronate in children with OI types III and IV reduced vertebral fracture rates and improved mobility; alendronate data are extrapolated from that mechanistic rationale rather than from a comparable dedicated trial.

Glucocorticoid-induced osteoporosis (GIOP). Children receiving prednisone at 0.1 mg/kg/day or higher for 3 months or more are at significant risk for bone loss. The American College of Rheumatology 2022 GIOP guidelines conditionally recommend bisphosphonate therapy for children with a fracture history or a BMD Z-score below -2.0 in this setting [11]. Alendronate 1 mg/kg weekly (maximum 35 to 40 mg) is one of the recommended options.

Immobile children. Cerebral palsy and other neuromuscular conditions cause disuse osteoporosis through reduced mechanical loading. Bisphosphonate therapy in this group requires extra caution because hypocalcemia risk is higher and fracture patterns differ from ambulatory children. A calcium infusion protocol before initiating bisphosphonate therapy is used at some centers for non-ambulatory children with severe bone disease.

Regulatory and Documentation Requirements

Because alendronate use in children under 12 is off-label for most indications, physicians should document in the medical record the specific diagnosis, the bone density data supporting treatment, the alternatives considered, the consent discussion with parents, and the monitoring plan. Some insurers require prior authorization with supporting DXA results and specialist notes before approving alendronate in pediatric patients.

The FDA Safety and Innovation Act and subsequent legislation have expanded pediatric study requirements for new drugs, but older drugs like alendronate pre-date those requirements. The available prescribing information from Merck for Fosamax does not include weight-based dosing tables for children under 18, which means clinicians must rely on published literature, society guidance, and institutional protocols to define the appropriate dose and monitoring interval [4].

Alendronate's safety profile in adults is well established. The FIT trial (N=2 to 027 in the vertebral fracture arm, JAMA 1998) reported that adverse event rates including upper gastrointestinal events were comparable between alendronate and placebo over 3 years [1]. Pediatric safety data of comparable scale do not exist, which is why prospective monitoring in clinical practice serves a dual function: protecting the individual patient and contributing to the real-world evidence base that will eventually inform more definitive pediatric guidance.